Grainger S L, John V A, Shotton P A, Smith S E
Br J Clin Pharmacol. 1985;19 Suppl 2(Suppl 2):239S-244S. doi: 10.1111/j.1365-2125.1985.tb02769.x.
Plasma metoprolol concentrations and haemodynamic effects have been measured in six healthy male volunteers during once daily dosing with a 19/285 Oros system and twice daily dosing with 100 mg conventional tablets, on two separate occasions. Plasma drug concentrations throughout the day varied less with the Oros than with the conventional tablet regimen. Predosing concentrations were also higher with Oros but areas under the curve, after correcting for the differences in dose, were similar for the two preparations. Inhibition of exercise tachycardia was drug concentration dependent and was smoothly controlled through the day only with the Oros preparation. Predosing effects at steady-state were also greater for the Oros regimen. The decline in mean blood pressure, however, showed the same daily pattern for both regimens, and no significant differences were detected between Oros and conventional tablet treatments. The smoothness of the plasma profiles after Oros confirmed the controlled-release performance of the system in vivo and indicates its potential in the treatment of angina, cardiac arrhythmias and wherever it is important not to jeopardize steady selective beta-adrenoceptor blockade.
在六名健康男性志愿者中,分别在两个不同的时间段进行了研究,一次是使用19/285渗透泵系统每日给药一次,另一次是使用100毫克常规片剂每日给药两次,期间测量了血浆美托洛尔浓度和血流动力学效应。与常规片剂给药方案相比,使用渗透泵系统时全天的血浆药物浓度变化较小。使用渗透泵系统时给药前的浓度也较高,但在校正剂量差异后,两种制剂的曲线下面积相似。运动性心动过速的抑制作用取决于药物浓度,且仅使用渗透泵制剂时全天可实现平稳控制。在稳态下,渗透泵给药方案的给药前效应也更大。然而,两种给药方案的平均血压下降呈现相同的每日模式,且在渗透泵制剂和常规片剂治疗之间未检测到显著差异。渗透泵给药后血浆浓度曲线的平稳性证实了该系统在体内的控释性能,并表明其在治疗心绞痛、心律失常以及在任何不危及稳定的选择性β-肾上腺素能受体阻滞很重要的情况下的潜力。